TETRACICLINA HCL

TETRACYCLINE

Get in touch with us!












      I accept conditions of use and privacy policy of this website.

    I want to receive updated information on the latest news.

    An overview

    Tetracycline hydrochloride is an antibiotic with a wide spectrum of activity and have been used in the treatment of a large number of infections caused by susceptible organisms (chlamydias, mycoplasmas, rickettsias and spirochaetes, and also many aerobic and anaerobic Gram-positive and Gram-negative pathogenic bacteria, and some protozoa).

    • Product Type: bacteriostatic antibiotics
    • CAS Number: 64-75-5
    • Common Indications: pneumonia and other infections of the respiratory tract. Also in the treatment of acne and rosacea
    • Product Status: Commercial
    • Available Grades: Non-Micronized
    • Documentation: C· CEP, DMF, CoA, MSDS
    Tetracycline f

    Advantages

    Efficacy:

    • Bacteriostatic action over a wide range of bacteria.

    • Good safety profile and well tolerated.

    • Optimal cost-efficiency across Europe.

    Safety:

    • Rapidly and completely absorbed in the gastrointestinal tract.

    • Parenterally well-absorbed.

    Finished
    Dosage Forms

    Oral:

    Capsules:
    250 and 500 mg.

    Parenteral.

    Global market status

    0 M

    USD global market sales in 2023 

    0 MT

    consumed globally

    0 %

    Lorem ipsum solor

    Few API manufacturers to cover worldwide demand.

    Our API

    Tetracycline

    • Our API Tetracycline is manufactured in accordance with cGMP and stringent international quality standards.

    Quality

    • Our quality control follows every stage from development of analytical methods to the control of manufacturing process.

    Samples availables

    destacado
    MINOCYCLINE

    PATENT PROTECTION

    Logo OFF

    Contact us & obtain the technical sheet












        I accept conditions of use and privacy policy of this website.

      I want to receive updated information on the latest news.